GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PegBio Co 2565.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

3.70

+8.19%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About PegBio Co

Its shares trade on HKEX under the ticker 2565.HK. It has been listed since 27 May 2025.

PegBio Co., Ltd. is a biotechnology company, which engages in the research, development and production of innovative drugs in the field of chronic disease treatment. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2025-05-27. The firm's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The firm's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The firm's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
27 May 2025
Website
pegbio.com ↗

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • PegBio's PB-119 is a near-commercialized GLP-1 receptor agonist for chronic disease treatment.
  • PegBio's product candidates include PB-718, PB-1902, and PB-722 for metabolic diseases.
  • PegBio focuses on innovative drugs for type 2 diabetes, obesity, and NASH in the Health Care sector.

Weaknesses

  • PegBio's IPO date is 27 May 2025, which is a future date.
  • PegBio's products target rare diseases like congenital hyperinsulinemia with limited market size.
  • PegBio's headquarters in Hangzhou, China, may face regional market constraints.

Opportunities

  • PegBio's PB-2301 and PB-2309 target obesity and OIC, expanding market potential.
  • PegBio's focus on chronic disease treatment aligns with global health trends.
  • PegBio's product pipeline includes multiple candidates for metabolic diseases.

Threats

  • PegBio's GLP-1 receptor agonist faces competition from existing diabetes treatments.
  • PegBio's products for rare diseases like congenital hyperinsulinemia have small patient populations.
  • PegBio's IPO on 27 May 2025 is a future event, creating uncertainty.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.